Figure 1From: Efficacy of telbivudine in Taiwanese chronic hepatitis B patients compared with GLOBE extension study and predicting treatment outcome by HBV DNA kinetics at Week 24 A. Cumulative HBeAg seroconversion rates with continuous telbivudine treatment for 4 years in the ITT population of HBeAg-positive Taiwanese patients. B. HBsAg kinetics during telbivudine treatment. Back to article page